Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 05, 2015 10:35 PM ET


Company Overview of Oramed Pharmaceuticals Inc.

Company Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule that completed Phase IIa clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which is in pre-clinical trials for the treatment of type 2 diabetes. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.

Hi-Tech Park 2/4


PO Box 39098

Jerusalem,  91390


Founded in 2002


972 2 566 0001


972 2 566 0004

Key Executives for Oramed Pharmaceuticals Inc.

Chief Executive Officer, President and Executive Director
Age: 41
Total Annual Compensation: $381.3K
Chief Financial Officer, Treasurer and Secretary
Age: 41
Total Annual Compensation: $193.8K
Chief Operating Officer and Vice President of Business Development
Age: 45
Total Annual Compensation: $199.2K
Chief Scientific Officer and Director
Age: 75
Total Annual Compensation: $271.3K
Compensation as of Fiscal Year 2014.

Oramed Pharmaceuticals Inc. Key Developments

Oramed Completes Randomization of over 50% of Patients in Phase IIb Oral Insulin Study

Oramed Pharmaceuticals Inc. announced that 98 patients have already been enrolled in the Company's Phase IIb study of its oral insulin capsule, ORMD-0801, which represents more than 50% of the 180 patients expected to be recruited for the trial. The double-blind, randomized Phase IIb study for type 2 diabetes was initiated on June 30 and is designed to generate ample data for both efficacy and safety endpoints.

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 11, 2015

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 11, 2015., at 11:00 US Eastern Standard Time. Location: offices of Sullivan & Worcester LLP. Agenda: To re-elect six directors of the Company to hold office until next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal; to ratify the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the 2015 fiscal year; and to transact any other business as may properly come before the Annual Meeting or any adjournments thereof.

Oramed Pharmaceuticals Agrees to Investment and License Agreement in China with Sinopharm Capital Management Co. Ltd. and Hefei Life Science & Technology Park Investments and Development Co., Ltd

Oramed Pharmaceuticals announced that it agreed to an investment and license agreement in China with Sinopharm Capital Management Co. Ltd. and Hefei Life Science & Technology Park Investments and Development Co. Ltd. for $50 million plus royalty payments. Under the terms of the agreement, Sinopharm and Hefei will acquire a 10% stake in Oramed Pharma for $12 million and exclusive rights for oral insulin capsule ORMD-0801 for $38 million. Of the $38 million, $18 million will be paid once the license agreement is signed and the remaining $20 million will be paid once results are released for Oramed's ongoing Phase IIb trial in the U.S. Sinopharm and Hefei will also pay a 10% royalty on sales.

Similar Private Companies By Industry

Company Name Region
Pharmos Ltd. Middle East/Africa
Plantex Ltd. Middle East/Africa
Pharma Two B Ltd. Middle East/Africa
Biontech, Ltd. Middle East/Africa
MGC Pharmaceuticals Limited Middle East/Africa

Recent Private Companies Transactions

Private Placement
July 2, 2015
Private Placement
November 3, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Oramed Pharmaceuticals Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at